INCB086550
CAS No. : 2230911-59-6
(Synonyms: PD-1/PD-L1-IN-8)
| Size | Price | Stock |
|---|---|---|
| 5mg | $350 | In-stock |
| 10mg | $510 | In-stock |
| 25mg | $867 | In-stock |
| 50mg | $1214 | In-stock |
| 100mg | $1700 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-134884 |
| M.Wt: | 693.79 |
| Formula: | C41H39N7O4 |
| Purity: | >98 % |
| Solubility: | H2O : 83.33 mg/mL (ultrasonic;adjust pH to 3 with HCl);DMSO : 100 mg/mL (ultrasonic) |
INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research[1].
In Vitro:INCB086550 (0.1-10000 nM, 20 h) has no overt toxicity to pleural effusion fluids cells[1].
INCB086550 (1 µmol/L, 24 h) induces the dimerization of cell-surface PD-L1 and resulting in internalization[1].
In Vivo:INCB086550 (15, 200 mg/kg for Oral gavage, once or twice) inhibits greater than 90% of unoccupied cell surface PD-L1 in MDA-MB-231 mice model[1].
INCB086550 (2, 20, or 200 mg/kg for Oral gavage, b.i.d) inhibits tumor growth in MC38 huPD-L1 mice model[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- INCB086550
- Cat. No.:
- HY-134884
- Quantity:
Your information is safe with us.